Semaglutide vs Tirzepatide: What the Labels and Trials Show

    Short answer

    Semaglutide (Ozempic, Wegovy, Rybelsus) acts on the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) acts on the GIP and GLP-1 receptors. In SURMOUNT-5, average weight loss was larger with tirzepatide; in SURPASS-2, average HbA1c and weight drops were larger with tirzepatide. Stomach side effects lead both labels. Which one fits you is your prescriber's call.

    Semaglutide is the ingredient in Ozempic, Wegovy and Rybelsus, all from Novo Nordisk. Tirzepatide is the ingredient in Mounjaro and Zepbound, both from Eli Lilly. Below are the FDA label facts for each ingredient, plus the two published trials that compared them directly, drawn from the Ozempic (05/2026), Rybelsus and Ozempic tablets (01/2026), Wegovy (06/2026), Mounjaro (08/2026) and Zepbound (08/2026) labels. The choice between them belongs with you and your prescriber, so nothing here names a winner.

    The Short Answer

    One Receptor or Two

    Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors, two gut hormones that help regulate blood sugar and appetite.

    Each Ingredient Has Diabetes and Weight Brands

    Ozempic, Rybelsus and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are the brands whose labels include long-term weight reduction.

    Two Trials Compared Them Directly

    In adults with obesity, the SURMOUNT-5 trial found greater average weight loss with tirzepatide. In adults with type 2 diabetes, the SURPASS-2 trial on the Mounjaro label found larger average drops in HbA1c and weight with tirzepatide.

    Stomach Effects Lead Both

    Nausea, diarrhea, vomiting and constipation are the most common side effects for both ingredients. They show up most while the dose is being raised.

    Which Brands Contain Each Ingredient

    Most confusion comes from brand names, not ingredients. Find your own medicine first.

    BrandIngredientMakerForm
    OzempicSemaglutideNovo NordiskOnce-weekly injection
    Ozempic tabletsSemaglutideNovo NordiskOnce-daily tablet
    RybelsusSemaglutideNovo NordiskOnce-daily tablet
    WegovySemaglutideNovo NordiskOnce-weekly injection or once-daily tablet
    MounjaroTirzepatideEli LillyOnce-weekly injection
    ZepboundTirzepatideEli LillyOnce-weekly injection

    Semaglutide for Type 2 Diabetes

    Ozempic is a once-weekly injection for adults with type 2 diabetes, and Ozempic tablets are a once-daily option on a separate label. Rybelsus is a once-daily semaglutide tablet that shares that tablet label.

    The Ozempic injection label also covers lowering heart and kidney risks in certain adults with type 2 diabetes. Both tablet brands are approved for blood sugar control and for heart event risk reduction in high-risk adults with type 2 diabetes.

    Semaglutide for Weight Reduction

    Wegovy comes as a once-weekly injection or a once-daily tablet. Its label covers long-term weight reduction, heart event risk reduction in adults with heart disease and, for the injection, a liver condition called MASH.

    Tirzepatide for Type 2 Diabetes

    Mounjaro is a once-weekly injection for blood sugar control in adults and children 10 and older with type 2 diabetes. It is also approved to lower heart event risk in high-risk adults with type 2 diabetes.

    Tirzepatide for Weight Reduction

    Zepbound is a once-weekly injection for long-term weight reduction in adults with obesity, or overweight with a weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity.

    Brand-level comparisons: Ozempic vs Wegovy, Mounjaro vs Ozempic and Wegovy vs Zepbound.

    Not Meant to Be Combined

    The Wegovy and Zepbound labels both say using them with any other GLP-1 receptor agonist is not recommended. Tirzepatide and semaglutide are not taken together.

    The Two Head-to-Head Trials

    Two published trials put tirzepatide and semaglutide side by side. Every figure below is a group average from one trial.

    SURMOUNT-5SURPASS-2
    Who was in it751 adults with obesity, without type 2 diabetes1,879 adults with type 2 diabetes taking metformin
    What was comparedTirzepatide vs semaglutide, highest tolerated dose, once weeklyMounjaro 5 mg, 10 mg or 15 mg vs semaglutide 1 mg, once weekly
    Length72 weeks40 weeks
    Average weight change-20.2% vs -13.7% of body weight-7.6 kg to -11.2 kg vs -5.7 kg
    Average HbA1c changeNot applicable (no type 2 diabetes)-2.0 to -2.3 points vs -1.9 points
    DesignOpen-label, funded by Eli LillyOpen-label, funded by Eli Lilly

    SURMOUNT-5, in Adults With Obesity

    SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to tirzepatide or semaglutide at the highest dose they could tolerate, once weekly for 72 weeks. Average weight fell by 20.2% on tirzepatide and 13.7% on semaglutide, as published in the New England Journal of Medicine in July 2025.

    SURPASS-2, in Adults With Type 2 Diabetes

    SURPASS-2 compared Mounjaro 5 mg, 10 mg and 15 mg with semaglutide 1 mg for 40 weeks in 1,879 adults taking metformin. Average HbA1c fell by 2.0 to 2.3 points on Mounjaro versus 1.9 on semaglutide, and average weight fell by 7.6 kg to 11.2 kg versus 5.7 kg.

    What These Trials Leave Out

    Both trials were open-label and funded by Eli Lilly, and SURPASS-2 used semaglutide 1 mg rather than the higher doses now on the labels. They report group averages, which cannot tell you how your own body will respond.

    How to Use the Numbers

    Bring the trial name and the averages to your prescriber as a starting point. Your health history, other medicines and coverage all shape the decision.

    How the Dose Ladders Differ

    These are the steps each FDA label lists, quoted from the labels so the numbers make sense. They are the labels' own schedules, not a recommendation or a plan for you.

    Semaglutide Injections

    The Ozempic and Wegovy injection labels both start at 0.25 mg once weekly and step up after 4 weeks at a time. The Ozempic label tops out at 2 mg, and the Wegovy label recommends 2.4 mg for adult weight maintenance, with 7.2 mg as a maximum for some adults.

    Semaglutide Tablets

    Wegovy tablets and Ozempic tablets both start at 1.5 mg once daily for 30 days, while Rybelsus starts at 3 mg. Each tablet label has its own steps after that, and the Rybelsus label says its tablets and Ozempic tablets are not swapped milligram for milligram.

    Tirzepatide Injections

    The Mounjaro and Zepbound labels both start at 2.5 mg once weekly and increase in 2.5 mg steps after at least 4 weeks on each dose. Both list 15 mg as the adult maximum.

    No Conversion Between Them

    Milligram amounts of different molecules can't be compared, so a milligram of semaglutide says nothing about a milligram of tirzepatide. Your prescriber sets every step, and Pep AI never suggests a dose.

    Side Effects Reported on the Labels

    Side effects are a deciding worry for many readers. The weight-reduction trials on the Wegovy and Zepbound labels give the clearest like-for-like context available, read each against its own placebo.

    Side effectWegovy 2.4 mg vs placeboZepbound vs placebo
    Nausea44% vs 16%25-29% vs 8%
    Diarrhea30% vs 16%19-23% vs 8%
    Vomiting24% vs 6%8-13% vs 2%
    Constipation24% vs 11%11-17% vs 5%

    Reading the Two Columns

    The two label tables come from separate trials with different people, doses and lengths, and both labels say rates from one drug's trials cannot be directly compared with another's. Zepbound was tested at several maintenance doses, so its column shows the range across them.

    What the Head-to-Head Trial Saw

    In SURMOUNT-5, stomach effects were the most common side effects in both groups. Most were mild to moderate and happened mainly during dose increases.

    Full Guides for Each Ingredient

    The GLP-1 side effects guide sets out both labels' full tables and warning signs, and side effects by week covers when they tend to show up.

    Warnings Shared by Both Ingredients

    Boxed Warning: Thyroid C-Cell Tumors

    Every semaglutide and tirzepatide label carries a boxed warning because the ingredient caused thyroid C-cell tumors in rodents, and it is unknown whether this happens in people. None should be used with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2.

    Pancreatitis, Gallbladder and Kidneys

    The labels list acute pancreatitis, gallbladder disease and kidney injury linked to fluid loss from vomiting or diarrhea. Severe stomach pain that will not go away needs prompt medical attention.

    Low Blood Sugar, Eyes and Procedures

    Low blood sugar is more likely with insulin or a sulfonylurea, and diabetic eye complications are listed for people with type 2 diabetes. Tell your care team about any planned surgery that uses anesthesia or deep sedation.

    A Note on Birth Control Pills

    The Mounjaro and Zepbound labels include a note for people who use birth control pills. Ask your prescriber what it means for you if you use them.

    Track Either Ingredient in Pep AI

    After your prescriber decides, the daily work starts. Pep AI handles every brand of both ingredients.

    Every Brand in One Log

    Pep AI logs a weekly Ozempic, Wegovy, Mounjaro or Zepbound shot, or a daily tablet with its own schedule. When your prescriber changes your dose, the new amount goes on the same history, so your current step is always clear.

    Reminders That Fit Weekly or Daily

    Pep AI reminds you on shot day or tablet day, and each medicine keeps its own schedule. On iPhone, home-screen widgets, a Lock Screen Live Activity and an Apple Watch app show what is due at a glance.

    Symptoms, Day by Day

    Pep AI's side-effect log has a built-in list of GLP-1 symptoms, plus your own, each rated for severity on the day you log it. Your dose history keeps its dates too, so you can tell your prescriber what started when. More in the side effects tracker.

    A Report for Your Prescriber

    Pep AI turns your doses, injection sites, weight and daily meal totals into a PDF report you can share with your prescriber. It gives your prescriber a clear record when you talk through the options.

    Key takeaways

    • Semaglutide (Ozempic, Wegovy, Rybelsus) acts on GLP-1; tirzepatide (Mounjaro, Zepbound) acts on GIP and GLP-1.
    • In SURMOUNT-5, average weight loss was larger with tirzepatide; in SURPASS-2, average HbA1c and weight drops were larger with tirzepatide. Both were open-label and Lilly-funded, and averages are not a promise for one person.
    • Milligram amounts of different molecules can't be compared. There is no conversion between them.
    • Nausea, diarrhea, vomiting and constipation lead both labels, mostly while the dose is being raised.
    • Which medicine, which dose and any switch are decisions for you and your prescriber.

    Whatever your prescriber decides, keep the record.

    Doses, side effects, meals and weight for any GLP-1 brand, in one app. Pep AI is free to try on iPhone and Android: a free download with a 3-day free trial, then a subscription.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Ozempic (semaglutide) injection prescribing information, Novo Nordisk / FDA (revised 05/2026)
    2. Rybelsus and Ozempic (semaglutide) tablets prescribing information, Novo Nordisk / FDA (revised 01/2026)
    3. Wegovy (semaglutide) prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
    4. Mounjaro (tirzepatide) prescribing information, Eli Lilly / FDA (revised 08/2026)
    5. Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
    6. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36
    7. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515

    This page compares FDA prescribing information and published trials for general information. It is not medical advice and does not tell you which medicine or dose to take; that decision belongs to you and your prescriber. Dose steps are quoted from each label's own schedule, not as a plan for you. Pep AI is not affiliated with Novo Nordisk or Eli Lilly, and brand names are trademarks of their owners. If a symptom is severe or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026